{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibjf2dryfihw3k3xvm2zruqhbt73zfuifgasp2lskwwjwccfwcugm",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mjfrb6q3k4a2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihljmx6hlqozygywswt6akiuxghha7t2j535pfvvaqpidhdaxrvfq"
    },
    "mimeType": "image/jpeg",
    "size": 16311
  },
  "path": "/2026/04/13/spyre-ibd-drug-success-early-trial/?utm_campaign=rss",
  "publishedAt": "2026-04-13T11:00:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "chronic diseases",
    "drug development",
    "STAT+"
  ],
  "textContent": "The inflammatory bowel disease therapy succeeded in its first major testing, setting up a competition with several large drugmakers.",
  "title": "STAT+: Spyre Therapeutics IBD drug shows promise in early trial",
  "updatedAt": "2026-04-13T14:45:27.000Z"
}